top of page

Deerfield Management Managing Partner James Flynn discusses a new $600M venture fund the firm has raised and describes how it will be invested, including into AI companies

  • blonca9
  • Jun 2
  • 1 min read

He describes raising the fund, and his take on the current challenging environment in healthcare. Plus, his thoughts on AI specifically, and how Deerfield is adding new people to both participate in it and invest in it.





Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page